You just read:

Oral semaglutide demonstrated cardiovascular safety in people with type 2 diabetes and established cardiovascular disease or high cardiovascular risk in PIONEER 6 trial

News provided by

Novo Nordisk

12 Jun, 2019, 00:15 IST